Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStandard BioTools adopts enhanced executive severance plans with change-of-control protections through 2028
Filed May 28, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
high
CEO Michael Egholm receives separate severance plan with 250% of salary plus bonus if terminated after a change of control, plus 30 months health coverage—more generous than other executives' 150% package.
Item 5.02 verify on EDGAR → -
high
CFO Alex Kim and Chief Business Officer Sean Mackay entered new severance agreements providing 150% of salary plus bonus as lump sum if terminated within 12 months after a change of control, replacing prior 2024 arrangements.
Item 5.02 verify on EDGAR → -
medium
Executives terminated by August 27, 2026 receive 100% equity vesting acceleration even outside change-of-control scenarios, creating near-term retention incentive during potential strategic transition period.
Item 5.02 verify on EDGAR → -
medium
New 2026 Severance Plan runs through August 2028, while CEO's separate 2023 plan auto-renews annually unless company provides 12 months notice, creating different termination timelines for top executive.
Item 5.02 verify on EDGAR →
Summary
Standard BioTools has implemented new executive severance arrangements that significantly enhance change-of-control protections for its leadership team. The company adopted two separate plans: a 2026 plan covering CFO Alex Kim and Chief Business Officer Sean Mackay, and a more generous 2023 plan exclusively for CEO Michael Egholm.
These "golden parachute" provisions are designed to retain executives through potential M&A activity, with double-trigger protections requiring both a change of control and qualifying termination before payouts occur. Retail investors should note the timing and structure.
The plans include an unusual provision accelerating all unvested equity for executives terminated by August 27, 2026—just three months away—suggesting the company may be preparing for strategic alternatives or anticipating leadership changes. The CEO's separate, more lucrative arrangement (250% vs. 150% multiplier) and auto-renewing term creates different incentives than other executives face. Watch for: Any announcements of strategic reviews, M&A discussions, or executive departures before the August 27 equity acceleration deadline. The enhanced retention packages often precede sale processes or significant corporate restructuring.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Standard BioTools adopted new severance plans for executives, providing enhanced change-of-control protections through 2028.
Added in current filing · verify on EDGAR →
On May 21, 2026, the Board of Directors (the “Board”) of Standard BioTools Inc. (the “Company”) approved the Company’s 2026 Change of Control and Severance Plan and Participation Agreement thereunder (the “2026 Severance Plan”). The 2026 Severance Plan has a term until August 4, 2028.
The Board approved a new severance plan running through August 2028 for executive leadership excluding the CEO. CFO Alex Kim and Chief Business Officer Sean Mackay entered participation agreements on May 27, 2026, superseding their prior severance arrangements under the 2024 plan.
Added in current filing · verify on EDGAR →
Under the 2026 Severance Plan, if the executive’s employment is terminated outside of the period beginning three months before a Change of Control (as defined in the 2026 Severance Plan) and ending 12 months after a Change of Control (such period, the “Change of Control Period”) for a reason other than Cause (as defined in the 2026 Severance Plan) or the executive’s death or Disability (as defined in the 2026 Severance Plan), then, subject to the severance conditions provided in the 2026 Severance Plan, the executive will be entitled to receive the following severance benefits: • Continued payments (less applicable withholdings) totaling 100% of the executive’s annual base salary in effect as of the date of termination in equal installments over a period of 12 months. • A pro-rated lump-sum payment of the executive’s annual target bonus in effect immediately prior to the termination. • Reimbursement of costs of continued health coverage for the executive, his or her spouse, and/or his or her dependents, as applicable, for a period of up to 12 months. • If the termination occurs on or prior to August 27, 2026, 100% vesting acceleration of the executive’s then-outstanding and unvested equity awards
For terminations outside a change-of-control window, covered executives receive 12 months base salary, pro-rated target bonus, 12 months health coverage, and full equity vesting if terminated by August 27, 2026. This provides baseline protection for involuntary departures.
Added in current filing · verify on EDGAR →
Under the 2026 Severance Plan, if an executive’s employment is terminated within the Change of Control Period either (i) by the Company for a reason other than Cause or the executive’s death or Disability or (ii) by the executive for Good Reason (as defined in the executive’s Participation Agreement under the 2026 Severance Plan), then, subject to the severance conditions provided in the 2026 Severance Plan, the executive will be entitled to receive the following severance benefits: • A lump-sum payment (less applicable withholdings) totaling 150% of the sum of (x) his or her annual base salary (as in effect immediately before termination or immediately before the Change of Control, whichever is higher) plus (y) the greater of (A) his or her annual target bonus (as in effect immediately before termination or immediately before the Change of Control, whichever is higher) or (B) the average of the annual cash incentives actually paid to him or her for the three fiscal years preceding the year in which his or her termination occurs
If terminated within three months before through 12 months after a change of control, executives receive 150% of salary plus bonus as a lump sum, pro-rated target bonus, 18 months health coverage, and full equity vesting. This double-trigger protection incentivizes executives to remain through potential M&A transactions.
Added in current filing · verify on EDGAR →
Additionally, on May 21, 2026, the Board approved the 2023 Severance Plan. The 2023 Severance Plan has an initial term until August 4, 2028, subject to automatic one-year renewals thereunder unless non-renewed by the Company upon twelve months’ prior notice. The 2023 Severance Plan is intended to provide certain payments of cash severance and other benefits to certain members of the Company’s executive leadership team in the event of a qualifying termination of employment with the Company. On May 22, 2026, the Company’s Chief Executive Officer, Michael Egholm, Ph.D., entered into a participation agreement under the 2023 Severance Plan (the “Egholm Participation Agreement”), a copy of which is filed herewith as Exhibit 10.5. Dr. Egholm is the only participant under the 2023 Severance Plan.
CEO Michael Egholm has a separate severance plan with more generous terms: 200% base salary over 24 months for non-change-of-control terminations, and 250% of salary plus bonus as a lump sum with 30 months health coverage for change-of-control terminations. This reflects standard practice of enhanced CEO retention packages.
Event · Item 9.01 — Financial Statements and Exhibits
Standard BioTools adopted a 2026 Change of Control and Severance Plan with participation agreements for executives including CFO and CEO.
Added in current filing · verify on EDGAR →
2026 Change of Control and Severance Plan and Participation Agreement
The company adopted a new 2026 Change of Control and Severance Plan. This plan provides severance and change-of-control protections for executives, which is a standard retention mechanism but signals the company is updating its executive compensation arrangements. The plan replaces or supplements the prior 2023 plan.
Added in current filing · verify on EDGAR →
2026 Change of Control and Severance Plan Participation Agreement, dated as of May 27, 2026, by and between Standard BioTools Inc. and Alex Kim.
CFO Alex Kim entered into a participation agreement under the new 2026 plan on May 27, 2026. This formalizes his severance and change-of-control benefits, which typically include cash payments and equity acceleration if his employment is terminated following a corporate transaction.
Added in current filing · verify on EDGAR →
2023 Change of Control and Severance Plan and Participation Agreement, dated as of May 22, 2026, by and between Standard BioTools Inc. and Michael Egholm, Ph.D.
CEO Michael Egholm, Ph.D. entered into a participation agreement under the 2023 plan (not the new 2026 plan) on May 22, 2026. This suggests the CEO may have different or separately negotiated change-of-control terms compared to other executives who are under the 2026 plan.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
2026 Change of Control and Severance Plan Participation Agreement, dated as of May 27, 2026, by and between Standard BioTools Inc. and Sean MacKay.
Executive Sean MacKay also entered into a participation agreement under the 2026 plan on May 27, 2026. This provides him with similar change-of-control and severance protections as other plan participants.
Added in current filing · verify on EDGAR →
2023 Change of Control and Severance Plan Participation Agreement, as amended and restated.
The company amended and restated a participation agreement under the 2023 Change of Control and Severance Plan. This indicates modifications to existing severance arrangements, though the specific changes and affected executive are not detailed in this exhibit list.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 29, 2026 · How we verify